CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
CureVac N.V. (“CureVac” or the “Company”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that the underwriters of its previously announced public offering, which closed on February 1, 2021, have exercised in full their option to purchase an additional 750,000 of its common shares at the public offering price of $90.00 per common share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of common shares sold by the Company in the offering increased to 5,750,000, which resulted in aggregate gross proceeds to the Company of approximately $517.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.